Power-Pak C.E.
 Login Help  Forgot Password?
Professions: Topics:
November 20, 2009
For more CE topics, click here to go to uspharmacist.com

     
 

Initiating and Monitoring Pharmacotherapy
in Patients with Parkinson’s Disease

Supported by an educational grant from Teva Neuroscience

FACULTY
Michele A. Faulkner, PharmD
Associate Professor
Departments of Pharmacy Practice and Medicine
Creighton University

FINANCIAL DISCLOSURE
Michele A. Faulkner, PharmD reported the following relationships to products or devices she has commercial interests related to the content of this CE activity: member of the Speaker’s Bureau of Teva Neuroscience.

ACCREDITATION STATEMENT
Pharmacy

acpePostgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 430-000-09-003-H01-P; 430-000-09-003-H01-T
Credits:
2.0 hours (0.20 ceu)

TYPE OF ACTIVITY: Knowledge

Media: Internet

Estimated time to complete program:
Estimated time to complete this activity and posttest is 120 minutes.


Published: February 1, 2009 Expires: February 28, 2011

PROCEDURE
Please complete the posttest questions and program evaluation online at: www.powerpak.com (a username and password are required to access your account). Upon passing the exam with a score of 70% or better, you can print out your statement of credit immediately. You can also view your test history at any time and print out duplicate statements from the Web site.

Exam processing inquiries and other inquiries and booklet orders to:
CE Customer Service Manager (800) 825-4696

TARGET AUDIENCE
This accredited activity is targeted to pharmacists and pharmacy technicians.

GOAL
To provide direction to pharmacists regarding the initiation of therapy for Parkinson’s disease, treatment of comorbidities, and long-term medicaton management for optimization of patient outcomes.

EDUCATIONAL OBJECTIVES
After completing this activity, participants will be able to:

  1. Review the pathophysiology of Parkinson’s disease;*
  2. Discuss the risks versus the benefits of early initiation of medication therapy;*
  3. Describe available options for initial medication management of Parkinson’s disease;*
  4. Recognize common comorbidities associated with Parkinson’s disease and appropriate options for treatment;* and
  5. Discuss strategies for enhancing patient outcomes.
*Also applies to pharmacy technicians

Disclosure of Unlabeled Use and Disclaimer

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, and Teva Neuroscience.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

       
 
Copyright © 1997 - 2009 Postgraduate Healthcare Education LLC unless otherwise noted.
All rights reserved. Reproduction in whole or in part without permission is prohibited. Privacy Policy